Agents that act luminally to treat diarrhoea and constipation.

Nat Rev Gastroenterol Hepatol

University of Michigan Health System, 3912 Taubman Center, SPC 5362, Ann Arbor, MI 48109-5362, USA.

Published: November 2012

Diarrhoea and constipation are common clinical complaints that negatively affect quality of life, reduce work productivity and lead to considerable health-care expenditure. A variety of therapies have been used to treat these conditions. Unlike drugs that require systemic absorption to exert their effects, luminally acting agents improve diarrhoea and constipation by altering intestinal and/or colonic motility, as well as mucosal absorption and secretion, through a variety of mechanisms. Examples of luminally acting agents for diarrhoea include peripherally acting opiate analogues, enkephalinase inhibitors, bile-acid binding agents, nonabsorbed antibiotics, probiotics, bismuth-containing compounds, berberine and agents with possible effects on intestinal secretion or permeability. Luminally acting drugs for constipation include bulking agents, surfactants, osmotics, stimulants, chloride-channel activators, probiotics, drugs that increase delivery of bile acids to the colon and natural therapies such as prunes and hemp seed extract. As the physiological effects of luminally acting drugs are largely confined to the gastrointestinal tract, these agents are unlikely to cause adverse effects outside of the gastrointestinal tract.

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrgastro.2012.162DOI Listing

Publication Analysis

Top Keywords

luminally acting
16
diarrhoea constipation
12
effects luminally
8
acting agents
8
acting drugs
8
gastrointestinal tract
8
agents
7
acting
5
agents luminally
4
luminally treat
4

Similar Publications

CNT@NiFeO nanocomposite for phenobarbital removal: adsorption study and characterization.

Environ Sci Pollut Res Int

December 2024

Laboratório de Materiais Magnéticos Nanoestruturados (LaMMaN), Universidade Franciscana (UFN), Santa Maria, RS, Brazil.

The contamination of seas, rivers, lakes, and groundwater by industrial, hospital, and domestic effluents is a global health problem. Scientific approaches are needed to assess and mitigate the impacts of those pollutants, seeking more sustainable alternatives that meet established environmental standards. Among the various contaminants that are released into water sources, phenobarbital (PHEN), a long-acting barbiturate, applied as a hypnotic, sedative, and in the treatment of seizures is an aquatic pollutant, raises significant concerns for human health and the environment.

View Article and Find Full Text PDF

Physiologically Based Biopharmaceutics Modeling Coupled with Biopredictive Dissolution in Development of Bioequivalent Formulation for Mesalamine Enteric Coated Tablet: A Tough Nut to Crack.

AAPS PharmSciTech

December 2024

Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, 500090, Telangana, India.

Mesalamine is a locally acting anti-inflammatory drug used to treat mild to moderate ulcerative colitis. Because of complex formulation principle and high in vivo variability, development of bioequivalent formulation for mesalamine is challenging. Further, fed state possess significant challenges for bioequivalence (BE) due to interplay of multiple factors.

View Article and Find Full Text PDF

Objectives: Crohn's perianal fistula represents a challenging condition to treat. Sphincters-preserving surgical techniques are increasingly being adopted as repeated surgical procedures may lead to various degrees of incontinence. This prospective study aims to assess the long-term efficacy of collagen paste application in patients with simple and complex Crohn's perianal fistulas.

View Article and Find Full Text PDF

Background And Aims: The ongoing antimicrobial resistant crisis heralds the need for new therapeutics against enteric infection. In mouse models, colon epithelial peroxisome proliferator-activated receptor-γ (PPAR-γ) signaling limits oxygen and nitrate luminal bioavailability, thereby preventing bacterial pathogen colonization. However, whether this mechanism operates similarly in humans remains uncertain.

View Article and Find Full Text PDF

Objective: To explore the mechanism of Lingze Tablets (LZT) acting on BPH in rats based on the VEGFA/TNF/IL-6 signaling pathway.

Methods: We equally randomized 30 SPF SD male rats into five groups, normal control, BPH model control, low-dose LZT, medium-dose LZT and high-dose LZT, and established a BPH model in the latter four groups by induction with non-castrate testosterone propionate. After the modeling, we treated the rats in the normal and model groups by intragastrical administration of physiological saline, and those in the latter three groups with low-, medium-, and high-dose LZT respectively, all for 28 successive days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!